[Oncolytic adenovirus expressing CCL19 enhances immunity against gastric cancer in mice]

Zheng Chen1, Jiheng Liu1, Dayong Xu2

  • 1Department of General Surgery, Changsha First Hospital, Changsha 410005, China.

Insights

Engineered oncolytic adenovirus Ad5-CCL19 effectively inhibits gastric cancer cell growth and activates anti-tumor immunity by enhancing T cell infiltration and cytokine secretion.

Area of Science:

  • Oncolytic virotherapy
  • Cancer immunology
  • Gastric cancer research

Background:

  • Oncolytic viruses are promising cancer therapeutics.
  • CCL19 is a chemokine that attracts immune cells.
  • Engineering oncolytic viruses to express immune-modulating factors is a novel strategy.

Purpose of the Study:

  • To investigate the efficacy of oncolytic adenovirus Ad5-CCL19 in inhibiting gastric cancer growth.
  • To evaluate the potential of Ad5-CCL19 to activate anti-tumor immune responses.

Main Methods:

  • Constructed Ad5-CCL19 by inserting mouse CCL19 gene into oncolytic adenovirus Ad5.
  • Assessed CCL19 expression via Western blotting.
  • Evaluated cytotoxicity using MTT assays and in vivo tumor models.
  • Analyzed immune cell infiltration (CD4+, CD8+) and cytokine secretion (IFN-γ, TNF-α) by immunofluorescence and flow cytometry.

Main Results:

  • Ad5-CCL19 successfully infected cells and secreted CCL19.
  • Demonstrated dose-dependent cytotoxicity against gastric cancer cells in vitro.
  • Showed superior tumor inhibition compared to Ad5 in vivo.
  • Significantly increased CD4+ and CD8+ T cell infiltration and elevated IFN-γ and TNF-α levels in tumor tissues.

Conclusions:

  • Ad5-CCL19 effectively inhibits gastric cancer cell growth.
  • Ad5-CCL19 enhances anti-tumor immune activity at the tumor site.

Related Concept Videos